Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
ABSTRACT Stopping treatment for osteoporosis with denosumab (Dmab) leads to a major and rapid loss in bone mineral density (BMD) and a risk of vertebral fracture. Subsequent treatment with bisphosphonate (Bp) does not completely prevent this bone loss. We carried out a prospective pilot study to fin...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2023-07-01
|
| Col·lecció: | JBMR Plus |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/jbm4.10731 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|